Sun.Feb 11, 2024

article thumbnail

Why One Google Cloud Exec Thinks HHS’ New Cybersecurity Guidelines Are A Step In The Right Direction

MedCity News

HHS recently published guidance outlining voluntary cybersecurity performance goals for the healthcare sector. Taylor Lehmann, a cybersecurity executive at Google Cloud, noted that “what is on HHS paper will most likely become what is in the actual final rulemaking or new regulatory requirements that become law.

article thumbnail

Pfizer/BioNTech COVID jab to be sold privately in UK

pharmaphorum

MHRA license change means people in GB will be able to buy Pfizer’s COVID-19 vaccine Comirnaty at retail pharmacies from March

Retail 82
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Navigating Tomorrow’s Behavioral Health with Compassion and Innovation

MedCity News

As we forge ahead in the behavioral health field, finding the right balance between technological solutions and whole-person care will be essential. Workforce challenges, changes to the way reimbursements work, new medication monitoring options and a laser focus on the personalized solutions that specialty pharmacies can provide are all trends to watch.

Medical 102
article thumbnail

Avoid Clinical Manufacturing Pitfalls With These 4 Tech Transfer Best Practices

PharmaTech

Webinar Date/Time: Tue, Mar 5, 2024 2:00 PM EST

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

“The Name May Be ‘Neue’ but Their Problems are Old”: Will Bright Health’s Rebrand Save It?

MedCity News

Bright Health Group recently announced that it is adopting NeueHealth as its corporate brand name after it shed its insurance business and is focusing on its value-based consumer care business. But getting rid of the Bright Health name doesn’t get rid of its financial problems, experts say.

Insurance 101
article thumbnail

This Biotech Startup Just Raised $105M to Extinguish Inflammation at the Source

MedCity News

Cour Pharmaceuticals’ nanoparticles reprogram the immune system to stop inflammation behind autoimmune disease. Three big pharma companies joined the startup’s Series A financing, which will fund clinical trials in type 1 diabetes and myasthenia gravis.

Pharma 101